Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMSV60C)

Drug Name

MEDI0382 Drug Info

Synonyms

Cotadutide; UNII-QL6A9B13HW; QL6A9B13HW; Cotadutide [INN]; Cotadutide [USAN]; MEDI-0382; MEDI 0382 [WHO-DD]; 1686108-82-6; His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Lys-(gamma-glupalmitoyl)-Ser-Glu-Tyr-Leu-Asp-Ser-Glu-Arg-Ala-Arg-Asp- Phe-Val-Ala-Trp-Leu-Glu-Ala-Gly-Gly; Glycine, L-histidyl-L-seryl-L-glutaminylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-alpha-aspartyl-N6-(N-(1-oxotetradecyl)-L-gamma-glutamyl)-L-lysyl-L-seryl-L-alpha-glutamyl-L-tyrosyl-L-leucyl-L-alpha-aspartyl-L-seryl-L-alpha-glutamyl

Indication

Disease Entry	ICD 11	Status	REF
Type-2 diabetes	5A11	Phase 2	[1]

Cross-matching ID

PubChem CID: 134694273
CAS Number: CAS 1686108-82-6
TTD Drug ID: DMSV60C

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Glucagon (GCG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PB-1023	DMZCI04	Type-2 diabetes	5A11	Phase 2	[2]
MK-8521	DMVNAYE	Type-2 diabetes	5A11	Phase 2	[2]
JNJ-64565111	DMVSUH1	Obesity	5B81	Phase 2	[2]
PT320	DMZYKXN	Parkinson disease	8A00.0	Phase 2	[3]
SAR425899	DM53IPE	Diabetic complication	5A2Y	Phase 1	[2]
ZP2929	DMRVDUM	Type-1 diabetes	5A10	Phase 1	[2]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Glucagon (GCG)	TT0NUFM	GLUC_HUMAN	Agonist	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT03596177) A Study to Evaluate the Effect of MEDI0382 on Energy Balance in Overweight and Obese Participants With Type 2 Diabetes Mellitus. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Sustained Release GLP-1 Agonist PT320 Delays Disease Progression in a Mouse Model of Parkinson's Disease. ACS Pharmacol Transl Sci. 2021 Mar 16;4(2):858-869.